丹参多酚酸盐注射液对慢性阻塞性肺疾病急性加重期患者的炎症调节作用及临床疗效分析

目的观察丹参多酚酸盐对慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效及其对IL-10、IL-6、TNF-α表达水平的影响。方法选择AECOPD患者92例,随机分为治疗组和对照组,每组46例。对照组给予西医常规疗法,治疗组在对照组基础上给予丹参多酚酸盐注射液。两组疗程均为10天,观察临床疗效及IL-10、IL-6、TNF-α的变化情况。结果治疗组和对照组总有效率分别为95.6%和82.6%,治疗组临床疗效优于对照组(P0.05)。治疗后,治疗组呼吸困难消失和肺部啰音消失时间均显著短于对照组(P0.05);治疗组和对照组FEV1占预计值百分比和FEV1/FVC均显著改善(P0.05),治疗组优于对照组(P0.05);两组IL-10均升高,IL-6和TNF-α均降低(P0.05,P0.01),治疗组与对照组差异有统计学意义(P0.01)。结论丹参多酚酸盐可以改善AECOPD患者的临床症状,并调节IL-10、IL-6、TNF-α水平的表达。

Analysis on regulatory effect and clinical efficacy of Salvianolate Injection for the treatment of acute exacerbation of chronic obstructive pulmonary disease

Objective To observe the clinical efficacy of salvianolate on patients with acute exacerbation of chronic obstructive pulmonary disease （AECOPD） and its effect on IL-10, IL-6 and TNF-α expression. Methods Ninety-two cases with AECOPD were randomized into treatment group and control group, with 46 cases in each group. Contrel group was treated by western medicine, and treatment group was added with Salvianolate Injection, with the course of 10 days. The clinical efficacy and changes of IL- 10, IL-6 and TNF-α were observed. Results The overall effective rate was 95.6% in the treatment group and 82.6% in the control group, with a difference between the two groups（P 〈0.05）. After treatment, the time disappearance of breath difficult and-wheeze in the treatment group was shorter than that of the controls （P 〈 0. 05 ） ; the FEVI and FEVI/FVC were significantly improved in these two groups （P 〈 0.05 ）. However, the improvement in treatment group was better than that of the control group （P 〈 0.05 ）. In both group, IL-10 was increased, but levels of IL-6 and TNF-α were decreased （P 〈 0.05, P 〈 0.01 ）. There was a significant difference between the two groups （ P 〈 0. 01 ）. Conclusion Salvianolate can improve the clinical efficacy and influence the expression of IL-10, IL-6 and TNF-α effectively to treat AECOPD patients.